ProGRP and NSE in therapy monitoring in patients with small cell lung cancer

Anticancer Research

Volumn 28, Issue 5 B, 2008, Pages 3027-3033

  Wójcik, Ewa ^a   Kulpa, Jan K ^a,b   Sas Korczyńska, Beata ^a   Korzeniowski, Stanisław ^a   Jakubowicz, Jerzy ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Monitoring of therapy; NSE; ProGRP; Small cell lung cancer

Indexed keywords

CISPLATIN; CYTOKERATIN 19; ETOPOSIDE; LACTATE DEHYDROGENASE; NEURON SPECIFIC ENOLASE; PROGASTRIN RELEASING PEPTIDE;

ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CISPLATIN; ENVIRONMENTAL MONITORING; ETOPOSIDE; HUMANS; KERATINS; L-LACTATE DEHYDROGENASE; LUNG NEOPLASMS; PEPTIDES; PHOSPHOPYRUVATE HYDRATASE; PROGNOSIS; PROTEIN PRECURSORS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 55749100686     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Aoyaki K, Miyake Y, Urakami K, Kashiwakuma T, Hasegawa A, Kodama T and Yamaguchi K: Enzyme immunoassay of immunoreactive pro-gastrin-releasing peptide (31-98) as tumor marker for small cell lung carcinoma: development and evaluation. Clin Chem 41: 537-543, 1995.
2. Lamy PJ, Grenier J, Kramar A and Pujol JJ: Pro-gastrin releasing peptide, neuron-specific enolase and chromogranin A as serum markers of small cell lung cancer. Lung Cancer 29: 197-203, 2000.
3. Jorgensen LGM, Osterlind K, Genolla J, Gomm SA, Hernandez JR, Johnson PWM, Lober J, Splinter TAW and Szturmowicz M: Serum neuron-specific enolase (S-NSE) and the prognosis in small cell lung cancer (SCLC): a combined multivariable analysis on data from nine centers. Br J Cancer 74: 463-467, 1996.
4. Carney DN and Telling M: Neuron-specific enolase: how useful as a cancer marker? Eur J Cancer Clin Oncol 24: 825-828, 1988.
5. Jorgensen LGM, Hansen HH and Cooper EH: Neuron-specific enolase, carcinoembryonic antigen and lactate dehydrogenase as indicators of disease activity in small cell lung cancer. Eur J Cancer Clin Oncol 25: 123-128, 1989.
6. Johnson PWM, Joel SP, Love S, Butcher M, Pandian MR, Squires L, Wrigley PFM and Slevin ML: Tumor markers for prediction of survival and monitoring of remission in small cell lung cancer. Br J Cancer 67: 760-766, 1993.
7. Ando S, Suzuki M, Yamamoto N, Iida T and Kimura H: The prognostic value of both neuron-specific enolase (NSE) and CYFRA 21-1 in small cell lung cancer. Anticancer Res 24(3B): 1941-1946, 2004.
8. Shibayama T, Ueoka H, Nishii K, Kiura K, Tabata M, Miyatake K, Kitajima T and Harada M: Complementary roles of progastrin-releasing peptide (ProGRP) and neuron-specific enolase (NSE) in diagnosis and prognosis of small cell lung cancer (SCLC). Lung Cancer 32: 61-69, 2001.
9. Kulpa J, Wójcik E, Reinfuss M and Kołodziejski L: Carcinoembrionic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem 48(11): 1931-1937, 2002.
10. Cuttitta F, Federko J, Gu J, Lebacq-Verheyden A-M, Linnoila I and Battey JF: Gastrin-releasing peptide gene-associated peptides are expressed in normal human fetal lung and small cell lung cancer: a novel peptide family found in man. J Clin Endorcinol Metab 67: 576-583, 1988.
11. Miyake Y, Kodama T and Yamaguchi K: Pro-gastrin-releasing peptide (31-98) is a specific tumor marker in patients with small cell lung carcinoma. Cancer Res 54: 2136-2140, 1994.
12. Nordlund MS, Fermer Ch, Nilsson O, Warren DJ and Paus E: Production and characterization of monoclonal antibodies for immunoassay of the lung cancer marker proGRP. Tumor Biol 28: 100-110, 2007
13. Okusaka T, Eguchi K, Kasai T, Kurata T, Yamamoto N, Ohe Y, Tamura T, Shinkai T and Saijo N: Serum levels of pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer. Clin Cancer Res 3: 123-127, 1997.
14. Molina R, Auge JM, Filella X, Vinolas N, Alicarte J, Domingo JM and Ballesta AM: Pro-gastrin-releasing peptide (ProGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer. Anticancer Res 25: 1773-1778, 2005.
15. Takada M, Kusunoki Y, Masuda N, Matui K, Yana T, Ushijima S, Lida K, Tamura K, Komiya T, Kawase I, Kikui N, Morino H and Fukuoka M: Pro-gastrin-releasing peptide (31-98) as a tumor marker of small cell lung cancer comparative evaluation with neuron-specific enolase. Br J Cancer 73: 1227-1232, 1996.
16. Stieber P, Dienemann H, Schalhorn A, Schmitt UM, Reinmiedl J, Hofmann K and Yamaguchi K: Pro-gastrin-releasing peptide (ProGRP) - a useful marker in small cell lung carcinomas. Anticancer Res 19: 2673-2678, 1999.
17. Molina R, Auge JM, Alicarte J, Fillela X, Vinolas N and Ballesta AM: Pro-gastrin-releasing peptide in patients with benign and malignant diseases. Tumor Biol 25: 56-61, 2004.
18. Niho S, Nishiwaki Y, Goto K, Ohmatsu H, Matsumoto T, Hojo F, Ohe Y, Kakinuma R and Kodama T: Significance of serum progastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron specific enolase and carcinoembryonic antigen. Lung Cancer 27: 159-167, 2000.
19. Schneider J, Philipp M, Salewski L and Velcovsky H-G: Progastrin-releasing peptide (ProGRP) and neuron-specific enolase (NSE) in therapy control of patients with small cell lung cancer. Clin Lab 49: 35-42, 2003.
20. Sunaga N, Tsuchiya S, Minato K, Watanabe S, Fueki N, Hoshino H, Makimoto T, Ishihara S, Saito R and Mori M: Serum progastrin-releasing peptide is a useful marker for treatment monitoring and survival in small cell lung cancer. Oncology 57: 143-148, 1999.
21. Harding M, McAllister J, Hulks G, Vernon D, Monie R, Paul J and Kaye SB: Neurone specific enolase (NSE) in small cell lung cancer: a tumour marker of prognostic significance? Br J Cancer 61: 605-607, 1990.
22. Akoun GM, Scarna HM, Milleron BJ, Benichou MP and Herman DP: Serum neuron-specific enolase. A marker for disease extent and response to therapy for small cell lung cancer. Chest 87: 39-43, 1985.
23. Fizazi K, Cojean I, Pignon J-P, Rixe O, Gatineau M, Hadef S, Arriagada R, Baldeyrou P, Comoy E and Le Chevalier T: Normal serum neuron-specific enolase (NSE) value after the first cycle of chemotherapy. An early predictor of complete response and survival in patients with small cell lung carcinoma. Cancer 82: 1049-1055, 1998.
24. Yamaguchi K, Aoyagi K, Urakami K, Fukutani T, Maki N, Yamamoto S, Otsubo K, Miyake Y and Kodama T: Enzyme immunosorbent assay of progastrin-releasing peptide for small cell lung cancer patients in comparison with neuron-specific enolase measurement. Jpn J Cancer Res 86: 698-705, 1995.
25. Vogelzang NJ, Nelimark RA and Nath KA: Tumour lysis syndrome after induction chemotherapy of small cell bronchogenic carcinoma. JAMA 249: 513-514, 1983.
26. Pujol JL, Quantin X, Jacot W, Boher JM, Grenier J and Lamy P-J: Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer. Lung Cancer 39: 131-138, 2003.
27. Oremek GM, Sauer-Eppel H and Bruzdziak TH: Value of tumor and inflammatory markers in lung cancer. Anticancer Res 27(4A): 1911-1915, 2007.